Group 1 - The company ST HuLuWa expects a net loss attributable to shareholders of the parent company between -210 million to -310 million yuan for the year 2025, indicating a decline compared to the same period last year [1] - The primary reasons for the performance change include adjustments in industry policies and market environment, leading the company to proactively modify the sales model for certain clients and optimize marketing channel layouts, resulting in decreased product sales and gross margin levels [1] - The completion and capitalization of the Haikou Meian Children's Medicine Intelligent Manufacturing Base and the second phase of the Guangxi Weiwei production base have led to increased fixed asset depreciation expenses, alongside rising bank loan interest expenses and ongoing R&D investments, which have negatively impacted the company's operating performance for the reporting period [1] Group 2 - Despite facing challenges from industry fluctuations, the company has implemented relevant countermeasures, including optimizing customer management, promoting customer tiered management, and enhancing cooperation depth with high-quality clients [1] - The company is also focusing on deepening cost control and improving operational efficiency through refined management practices, strictly controlling expenditure, and striving to enhance operating performance by reducing costs and increasing efficiency [1]

Core Viewpoint - ST HuLuWa announced an expected net profit attributable to shareholders of the listed company for the year 2025 to be between -210 million and -310 million yuan, indicating a significant loss forecast [1] - The company also projected a net profit attributable to shareholders after deducting non-recurring gains and losses for 2025 to be between -250 million and -350 million yuan, further emphasizing the anticipated financial challenges [1] Financial Projections - Expected net profit for 2025: -210 million to -310 million yuan [1] - Expected net profit after non-recurring items for 2025: -250 million to -350 million yuan [1]

一、关于公司被实施其他风险警示的基本情况 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2026-008 海南葫芦娃药业集团股份有限公司 关于公司股票被实施其他风险警示相关事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 海南葫芦娃药业集团股份有限公司（以下简称"公司"）2024年度内部控制被 出具否定意见审计报告，根据《上海证券交易所股票上市规则》第9.8.1条规定，公司 股票于2025年4月30日起被实施其他风险警示。 ● 根据《上海证券交易所股票上市规则》第9.8.5条："上市公司股票因第9.8.1 条第一款第（二）项至第（五）项规定情形被实施其他风险警示的，在被实施其他风险 警示期间，公司应当至少每月披露1次提示性公告，分阶段披露涉及事项的解决进展情 况"。公司将每月披露一次其他风险警示相关事项的进展情况，提示相关风险。 8、公司围绕合规管理核心目标，积极加强与监管部门的沟通联系，加强风险防控 体系建设。组织核心人员参与监管政策解读会议，聚焦内部控制、信息披露等政策调整； ...

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2026-009 海南葫芦娃药业集团股份有限公司 关于全资子公司获得依巴斯汀口服溶液药品注册证书的 公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司全资子公司广西维威制药有限公司（以下简 称"广西维威"）近日收到国家药品监督管理局（以下简称"国家药监局"）核准签 发的关于依巴斯汀口服溶液的《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药物名称：依巴斯汀口服溶液 剂型：口服溶液剂 注册分类：化学药品 3 类 规格：120ml：120mg 上市许可持有人：广西维威制药有限公司 受理号：CYHS2302665 药品批准文号：国药准字 H20263275 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品研发及相关 依巴斯汀口服溶液适用于伴有或不伴有过敏性结膜炎的过敏性鼻炎（季节性和 常年性）。慢性特发性荨麻疹的对症治疗。 截至目前，公司对该产品已 ...

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2026-007 海南葫芦娃药业集团股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本期业绩预告适用于净利润为负值的情形。 ● 海南葫芦娃药业集团股份有限公司（以下简称"公司"）预计 2025 年度实 现归属于上市公司股东的净利润-21,000 万元到-31,000 万元; 预计 2025 年度实现 归属于上市公司股东的扣除非经常性损益的净利润-25,000 万元到-35,000 万元。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （一）受行业政策调整和市场环境变化等因素影响，公司主动调整部分客户的 销售模式，优化营销渠道布局，上述经营策略的调整致使公司本报告期的产品销售 及毛利率水平有所下降。 （二）公司海口美安儿童药智能制造基地和广西维威二期生产基地建成并转固， 导致固定资产折旧费用增加；同时，公司银行借款利息费用化增加以及研发持续投 入 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of Ebastine oral solution, which is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria [1] Group 1 - The full subsidiary of the company, Guangxi Weiwei Pharmaceutical Co., Ltd., is responsible for the newly approved Ebastine oral solution [1] - The Ebastine oral solution is suitable for treating allergic rhinitis (both seasonal and perennial) with or without allergic conjunctivitis, as well as chronic idiopathic urticaria [1]

Core Viewpoint - The company ST HuLuWa expects to report a net profit attributable to shareholders of the listed company in the range of negative 210 million to negative 310 million yuan for the fiscal year 2025, indicating a significant financial downturn due to industry policy adjustments and changes in market conditions [1] Group 1: Financial Performance - The anticipated net profit for 2025 is projected to be between negative 210 million yuan and negative 310 million yuan [1] - The company's product sales and gross profit margin levels have declined as a result of strategic adjustments in response to market conditions [1] Group 2: Strategic Adjustments - The company has proactively adjusted the sales models of certain clients and optimized its marketing channel layout [1] - These operational strategy adjustments are directly linked to the observed decline in sales and profitability [1]

Group 1 - The company ST HuLuWa announced that as of the disclosure date, there are no guarantees provided to entities outside the consolidated financial statements [1] - The total external guarantee balance of the company and its subsidiaries is approximately 255 million yuan, accounting for 36.44% of the latest audited net assets [1] - The guarantee balance for the company's subsidiaries is about 245 million yuan, representing 35.01% of the latest audited net assets [1] Group 2 - The investigation into the "Jie Wo Rui" platform under Shui Bei Gold reveals a leverage of 40 times, leading to losses as gold prices rise [1] - The platform's owner claims to still be in Shenzhen, while investors express dissatisfaction with the proposed repayment plan, which offers only 20% of the principal [1]

海南葫芦娃药业集团股份有限公司 关于广西维威制药有限公司为其全资子公司 提供担保的公告 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2026-006 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 本次担保金额 | 实际为其提供的 担保余额（不含本 | 是否在前期预计 | 本次担保是否有 | | --- | --- | --- | --- | --- | | | | 次担保金额） | 额度内 | 反担保 | | 来宾市维威药物提 取有限公司 | 1000.00 万元 | 1000.00 万元 | 是 | 否 | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 25,529.79（不含本次） | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 36.44 | | 特别风险提示（如有请勾选） | □担保金额（含本次）超过上市公司最近一 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 责任编辑：韦子蓉 登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 信本股民索赔团队提醒，ST葫芦娃已收到证监会立案告知书，立案调查程序启动。因此受损的投资 者，可通过"新浪股民维权平台"自愿登记索赔。 维权条件： 葫芦娃：符合以下条件的投资者可发起索赔，于2024年8月29日—2025年4月22日期间买入且有持仓，无 论在2025年4月23日及之后是否卖出。（注：具体赔付范围由法院最终确定）（葫芦娃维权入口） （本文由上海市信本律师事务所合伙人赵敬国律师供稿，不代表新浪财经的观点。赵敬国律师，于1999 年取得律师资格，法学理论知识扎实，曾在高校任教。2004年起开始律师执业，承办过千余起各类诉讼 案件，积累了十分丰富的争议处理经验，尤其擅长处理 ...